Search
Search Results
-
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
Composite outcome measures such as progression-free survival and disease-free survival are increasingly used as surrogate end points in oncology...
-
Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis
PurposeGlioblastomas, the most common primary malignant brain tumors in adults, still hold poor prognosis. Corticosteroids, such as dexamethasone,...
-
Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients
PurposeSarcopenia may complicate treatment in cancer patients. Herein, we assessed whether sarcopenia measurements derived from radiation planning...
-
Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas
PurposePrimary treatment of spinal ependymomas involves surgical resection, however recurrence ranges between 50 and 70%. While the association of...
-
Association Between Hormonal Maintenance Therapy and Progression-Free Survival in Advanced Epithelial Ovarian Cancer Patients: A Retrospective Study
IntroductionThis retrospective study aimed to investigate the association between hormonal maintenance therapy and progression-free survival (PFS) in...
-
A Nomogram Including Sarcopenia for Predicting Progression-Free Survival in Patients with Localized Papillary Renal Cell Carcinoma: A Retrospective Cohort Study
BackgroundBecause of to the removal of subclassification of papillary renal cell carcinoma (pRCC), the survival prognostification of localized pRCC...
-
Impact of Choroidal Melanoma Characteristics on Progression-Free Survival in Patients Undergoing Hypofractionated Stereotactic Photon Radiotherapy
IntroductionIn an effort to replace ultrasonography-based thickness measurements, we investigated whether choroidal melanoma characteristics are...
-
Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review
PurposePatients with locally advanced or metastatic differentiated thyroid cancer (DTC) have a variable prognosis, and the development of more...
-
Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients
Background and ObjectiveCetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal immunoglobulin (Ig)G1 antibody, has been approved for...
-
Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer
BackgroundInterrupting chemotherapy may explain the reduced overall survival (OS) in patients with pancreatic cancer (PC) with cholangitis....
-
Postoperative [68Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1
PurposeTumor resection represents the first-line treatment for symptomatic meningiomas, and the extent of resection has been shown to be of...
-
Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
ObjectivesThis study aims to establish nomograms to accurately predict the overall survival (OS) and progression-free survival (PFS) in patients with...
-
High-density lipoprotein (HDL) has an impact on myeloma outcome: Lower HDL associates with worse progression-free survival
BackgroundMultiple myeloma (MM) staging is based on beta‑2 MG, albumin, LDH levels, and the presence of chromosomal abnormalities. We aimed to...
-
Predicting the progression-free survival of gastrointestinal stromal tumors after imatinib therapy through multi-sequence magnetic resonance imaging
PurposeIdentify radiomics features associated with progression-free survival (PFS) and develop a predictive model for accurate PFS prediction in...
-
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
BackgroundHistorically, patient selection for peptide receptor radionuclide therapy (PRRT) has been performed by virtue of somatostatin receptor...
-
Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer
PurposeRegorafenib is the first multikinase inhibitor used for metastatic colorectal cancer (mCRC) treatment. Reports regarding other multikinase...
-
CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia
The clinical outcome of lymphocytic leukemia (CLL) is quite heterogeneous. The purpose of this observational study was to investigate the clinical...
-
Tumor and metastatic lymph nodes metabolic activity on 18F-FDG-PET/CT to predict progression-free survival in locally advanced cervical cancer
ObjectiveThe present study investigated the predictive diseases progression value of preoperative fluorodeoxyglucose (FDG) positron emission...
-
Multiparametric MRI-based fusion radiomics for predicting telomerase reverse transcriptase (TERT) promoter mutations and progression-free survival in glioblastoma: a multicentre study
PurposeThis study evaluated the performance of multiparametric magnetic resonance imaging (MRI)–based fusion radiomics models (MMFRs) to predict...
-
Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma
PurposeThyroid dysfunction is the most common immune-related adverse event during anti-programmed cell death 1 (anti-PD-1) therapy. In this study, we...
